Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1423
{ "count": 24882, "next": "http://api.gregory-ms.com/articles/?format=api&page=1424", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1422", "results": [ { "article_id": 439293, "title": "Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis", "summary": "<jats:p> Background </jats:p><jats:p> Although MRI measures of grey matter abnormality correlate with clinical disability in multiple sclerosis, it is uncertain whether grey matter abnormality measured on MRI is entirely due to a primary grey matter process or whether it is partly related to disease in the white matter. </jats:p><jats:p> Methods </jats:p><jats:p> To explore potential mechanisms of grey matter damage we assessed the relationship of white matter T2 lesion volume, T1 lesion volume, and mean lesion magnetisation transfer ratio (MTR), with MRI measures of tissue atrophy and MTR in the grey matter in 117 subjects with secondary progressive multiple sclerosis. </jats:p><jats:p> Results </jats:p><jats:p> Grey matter fraction and mean grey matter MTR were strongly associated with lesion volumes and lesion MTR mean ( r = ±0.63–0.72). In contrast, only weak to moderate correlations existed between white matter and lesion measures. In a stepwise regression model, T1 lesion volume was the only independent lesion correlate of grey matter fraction and accounted for 52% of the variance. Lesion MTR mean and T2 lesion volume were independent correlates of mean grey matter MTR, accounting for 57% of the variance. </jats:p><jats:p> Conclusions </jats:p><jats:p> Axonal transection within lesions with secondary degeneration into the grey matter may explain the relationship between T1 lesions and grey matter fraction. A parallel accumulation of demyelinating lesions in white and grey matter may contribute to the association of T2 lesion volume and lesion MTR with grey matter MTR. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509103176", "published_date": "2009-05-12T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 259805, "given_name": "J", "family_name": "Furby", "ORCID": null, "country": null }, { "author_id": 259806, "given_name": "T", "family_name": "Hayton", "ORCID": null, "country": null }, { "author_id": 259808, "given_name": "D", "family_name": "Altmann", "ORCID": null, "country": null }, { "author_id": 259809, "given_name": "R", "family_name": "Brenner", "ORCID": null, "country": null }, { "author_id": 259810, "given_name": "J", "family_name": "Chataway", "ORCID": null, "country": null }, { "author_id": 259812, "given_name": "KJ", "family_name": "Smith", "ORCID": null, "country": null }, { "author_id": 246262, "given_name": "DH", "family_name": "Miller", "ORCID": null, "country": null }, { "author_id": 251678, "given_name": "R", "family_name": "Kapoor", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.987958Z", "noun_phrases": [ "Different white matter lesion characteristics", "distinct grey matter abnormalities", "secondary progressive multiple sclerosis" ], "doi": "10.1177/1352458509103176", "access": "restricted", "takeaways": " MRI measures of grey matter abnormality correlate with clinical disability in multiple sclerosis . We assessed relationship of white matter T2 lesion volume, T1 lesionsion volume and mean lesion magnetisation transfer ratio (MTR) in 117 subjects with secondary progressive multiple sclerosis in the grey matter . We found grey matter fraction and mean grey matter MTR were strongly associated with lesion volumes and lesion MTR mean .", "categories": [] }, { "article_id": 439292, "title": "Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria", "summary": "<jats:p> Approximately 85% of multiple sclerosis (MS) cases begin as clinically isolated syndromes (CIS). Results from the Controlled High-Risk Subjects Avonex<jats:sup>®</jats:sup> Multiple Sclerosis Prevention Study (CHAMPS) demonstrated that, in patients with CIS, treatment with intramuscular (IM) interferon beta-1a (IFNβ-1a) 30 μg once weekly delayed conversion to clinically definite MS (CDMS) in the total population and in subgroups based on presenting syndromes and baseline magnetic resonance imaging (MRI) characteristics. Changes to clinical and MRI risk classification of presenting symptoms in recent studies prompted reanalysis of CHAMPS data. Presenting syndromes were assessed using a derived algorithm that stratifies patients into mono- or multifocal categories based on functional system scores. The ability of IM IFNβ-1a to delay progression to CDMS in subgroups based on clinical presentation and MRI characteristics was assessed. Reanalysis of CHAMPS patients showed that 30% could be classified by clinical criteria as having multifocal disease at baseline. IM IFNβ-1a initiated at a first demyelinating attack delayed CDMS in monofocal patients ( P = 0.0013), patients with or without gadolinium-enhancing lesions ( P = 0.0007, P = 0.0405) and patients with at least nine T2 lesions at baseline ( P = 0.0044). These data confirm that IM IFNβ-1a delays conversion to CDMS in patients with CIS. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509103173", "published_date": "2009-05-29T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 289840, "given_name": "P", "family_name": "O’Connor", "ORCID": null, "country": null }, { "author_id": 270923, "given_name": "RP", "family_name": "Kinkel", "ORCID": null, "country": null }, { "author_id": 293156, "given_name": "M", "family_name": "Kremenchutzky", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.986604Z", "noun_phrases": [ "Efficacy", "intramuscular interferon beta-1a", "patients", "clinically isolated syndrome", "analysis", "subgroups", "new risk criteria" ], "doi": "10.1177/1352458509103173", "access": "restricted", "takeaways": " Approximately 85% of multiple sclerosis (MS) cases begin as clinically isolated syndromes (CIS) Treatment with intramuscular (IM) interferon beta-1a delayed conversion to clinically definite MS (CDMS)", "categories": [] }, { "article_id": 439291, "title": "Multiple sclerosis in China—history and future", "summary": "<jats:p> Background </jats:p><jats:p> Multiple sclerosis (MS) is considered rare in China and reports on MS in the English literature are few. </jats:p><jats:p> Methods </jats:p><jats:p> A systematic literature search for articles with MS was made, particularly for papers published in the Chinese medical journals from mainland China. </jats:p><jats:p> Results </jats:p><jats:p> In China, the first case of MS was described in the medical records from Xiehe hospital in 1926, and the first autopsy case of MS was reported from Huashan hospital in 1957. Although reports on MS based on the information from hospital case-series have been increased gradually in the recent decades, there is no national surveillance on MS frequency in the population and population-based surveys on MS were few in China. Generally for Chinese patients with MS the mean age at onset of MS is around 30 years, with a few cases younger than 20 years; the most frequent site of the lesions in the central nervous system, based on the clinical symptoms or signs, is the spinal cord (usually more than 60%); there are few patients with a family history of MS; almost all patients are treated with corticosteroids. Reported prevalence rates of MS from population surveys in China are rather low (1–2 per 100,000) and higher in females than in males, which are comparable with the results from other populations in Asia. </jats:p><jats:p> Conclusion </jats:p><jats:p> The clinical and epidemiological aspects of MS in China are, in general, similar to that from other populations in Asia. Epidemiological studies and national surveillance on MS are required in China. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509102921", "published_date": "2009-05-12T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 303117, "given_name": "Q", "family_name": "Cheng", "ORCID": null, "country": null }, { "author_id": 310785, "given_name": "X-J", "family_name": "Cheng", "ORCID": null, "country": null }, { "author_id": 310786, "given_name": "G-X", "family_name": "Jiang", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.985314Z", "noun_phrases": [ "Multiple sclerosis", "China", "history", "future" ], "doi": "10.1177/1352458509102921", "access": "restricted", "takeaways": " Multiple sclerosis (MS) is considered rare in China and reports on MS in the English literature are few . There is no national surveillance on MS frequency in the population and population-based surveys on MS were few in China . The clinical and epidemiological aspects of MS in China are, in general, similar to that from other populations in Asia .", "categories": [] }, { "article_id": 439290, "title": "Regulation of matrix metalloproteinases and their inhibitors by interferon-β: a longitudinal study in multiple sclerosis patients", "summary": "<jats:p> Background </jats:p><jats:p> Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)-β is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN-β on the other 20 members of the MMP family. </jats:p><jats:p> Methods </jats:p><jats:p> This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN-β therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR. </jats:p><jats:p> Results </jats:p><jats:p> RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time. </jats:p><jats:p> Conclusions </jats:p><jats:p> These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN-β in MS for at least 6 months. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509102920", "published_date": "2009-04-21T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 284554, "given_name": "F", "family_name": "Bernal", "ORCID": null, "country": null }, { "author_id": 284555, "given_name": "B", "family_name": "Elias", "ORCID": null, "country": null }, { "author_id": 283474, "given_name": "HP", "family_name": "Hartung", "ORCID": null, "country": null }, { "author_id": 270068, "given_name": "BC", "family_name": "Kieseier", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.984083Z", "noun_phrases": [ "Regulation", "matrix metalloproteinases", "their inhibitors", "interferon", "a longitudinal study", "multiple sclerosis patients" ], "doi": "10.1177/1352458509102920", "access": "restricted", "takeaways": " Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes . Some members are implicated in immunopathogenesis of multiple sclerosis . Interferon (IFN)-β is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9 .", "categories": [] }, { "article_id": 439289, "title": "Accumulation of cortical lesions in MS: relation with cognitive impairment", "summary": "<jats:p> Background </jats:p><jats:p> Gray matter (GM) lesions are frequently found in multiple sclerosis (MS) and their in-vivo detection has been improved using new magnetic resonance imaging sequences, such as double inversion recovery (DIR). However, little is known about progression of GM lesions over time. </jats:p><jats:p> Objective </jats:p><jats:p> To study the longitudinal behavior of GM lesions and to explore their relation to cognitive impairment in MS. </jats:p><jats:p> Methods </jats:p><jats:p> DIR images were acquired from 13 MS patients and seven healthy controls at two time points with a median interval of 3 years. At follow-up, all subjects underwent cognitive testing. Lesions were classified as white matter, cortical or hippocampal lesions. </jats:p><jats:p> Results </jats:p><jats:p> In patients, median cortical lesion number had increased from 18 to 26 at follow-up ( P = 0.01), median white matter (WM) lesion number had increased from 56 to 65 ( P = 0.02), and no significant increase over time was found for hippocampal lesions. Cortical lesion number at follow-up was significantly higher in secondary progressive (SP) than in relapsing-remitting patients. Significant relations were found between cortical and WM lesion number at follow-up on the one hand and visuospatial memory and processing speed on the other hand. Hippocampal lesion number was related to visuospatial memory. </jats:p><jats:p> Conclusion </jats:p><jats:p> Cortical lesions increase significantly over a 3-year time period, are most frequent in SP patients, and are associated with cognitive impairment. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509102907", "published_date": "2009-05-12T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 293262, "given_name": "SD", "family_name": "Roosendaal", "ORCID": null, "country": null }, { "author_id": 267599, "given_name": "B", "family_name": "Moraal", "ORCID": null, "country": null }, { "author_id": 293263, "given_name": "PJW", "family_name": "Pouwels", "ORCID": null, "country": null }, { "author_id": 241207, "given_name": "H", "family_name": "Vrenken", "ORCID": null, "country": null }, { "author_id": 293266, "given_name": "JA", "family_name": "Castelijns", "ORCID": null, "country": null }, { "author_id": 241205, "given_name": "F", "family_name": "Barkhof", "ORCID": null, "country": null }, { "author_id": 271853, "given_name": "JJG", "family_name": "Geurts", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.983051Z", "noun_phrases": [ "Accumulation", "cortical lesions", "MS", "relation", "cognitive impairment" ], "doi": "10.1177/1352458509102907", "access": "restricted", "takeaways": " Gray matter (GM) lesions are frequently found in multiple sclerosis and their in-vivo detection has been improved using new magnetic resonance imaging sequences such as double inversion recovery (DIR) Little is known about progression of GM lesions over time .", "categories": [] }, { "article_id": 439288, "title": "Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis", "summary": "<jats:p> Background </jats:p><jats:p> Vitamin D is important for bone health and immune regulation, and has been shown to be low in multiple sclerosis (MS). We sought to determine the effect of over the counter low dose cholecalciferol (LDC) and high dose ergocalciferol (HDE) on the vitamin D levels in MS patients. </jats:p><jats:p> Methods </jats:p><jats:p> We retrospectively evaluated serum 25-hydroxy-vitamin D [25(OH)D] levels of 199 patients (CIS, n = 32; RRMS, n = 115; PPMS, n = 10; SPMS, n = 16; Transverse Myelitis (TM), n = 9; other neurological diseases, n = 16) attending our clinic between 2004 and 2008. We examined the change in 25(OH)D levels in 40 MS patients who took either LDC (≤800 IU/day) or HDE (50,000 IU/day for 7-10 days, followed by 50,000 IU weekly or biweekly). </jats:p><jats:p> Results </jats:p><jats:p> The average 25(OH)D level was 71 ± 39 nmol/L (Mean ± SD), and 167(84%) patients had insufficient levels (≤100 nmol/L) of 25(OH)D. The patients supplemented with LDC did not have a significant increase in their 25(OH)D levels. However, 25(OH)D levels increased by 42 nmol/L ( P = 0.01) in the patients originally taking LDC and then prescribed HDE. Optimal levels (≥100 nmol/L) were only achieved in less than 40% of patients. </jats:p><jats:p> Conclusions </jats:p><jats:p> We conclude that large numbers of patients with MS and TM in our cohort are deficient in vitamin D. HDE significantly elevated 25(OH)D levels in MS patients and was more effective at increasing 25(OH)D levels than LDC. Prospective studies are required to determine appropriate dosing regimen to achieve optimal levels in the majority of MS patients and to ascertain the safety, immunological response, and ultimately the clinical efficacy of vitamin D replacement therapy. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509102844", "published_date": "2009-04-21T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 306605, "given_name": "GS", "family_name": "Hiremath", "ORCID": null, "country": null }, { "author_id": 306606, "given_name": "D", "family_name": "Cettomai", "ORCID": null, "country": null }, { "author_id": 306607, "given_name": "M", "family_name": "Baynes", "ORCID": null, "country": null }, { "author_id": 306608, "given_name": "JN", "family_name": "Ratchford", "ORCID": null, "country": null }, { "author_id": 306609, "given_name": "S", "family_name": "Newsome", "ORCID": null, "country": null }, { "author_id": 306610, "given_name": "D", "family_name": "Harrison", "ORCID": null, "country": null }, { "author_id": 292888, "given_name": "D", "family_name": "Kerr", "ORCID": null, "country": null }, { "author_id": 306611, "given_name": "BM", "family_name": "Greenberg", "ORCID": null, "country": null }, { "author_id": 249733, "given_name": "PA", "family_name": "Calabresi", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.981718Z", "noun_phrases": [ "Vitamin D status", "effect", "low-dose cholecalciferol", "high-dose ergocalciferol supplementation", "multiple sclerosis" ], "doi": "10.1177/1352458509102844", "access": "restricted", "takeaways": " Vitamin D is important for bone health and immune regulation, and has been shown to be low in multiple sclerosis . We sought to determine the effect of over the counter low dose cholecalciferol (LDC) and high dose ergocalciferols (HDE) on vitamin D levels in MS patients . The average 25(OH)D level was 71 ±39 nmol/L (Mean ±SD), and 167(84%) patients had insufficient", "categories": [] }, { "article_id": 439287, "title": "The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions", "summary": "<jats:p> Objective </jats:p><jats:p> To evaluate the long-term costs and quality of life (QoL) with and without disease-modifying treatments (DMTs) of patients with multiple sclerosis (MS). </jats:p><jats:p> Methods </jats:p><jats:p> Data on resource consumption, productivity losses, QoL (utility), and fatigue were collected from 1355 patients registered with a patient association and descriptive analyses was performed. </jats:p><jats:p> A Markov model was developed to estimate costs and utility over 20 years using the survey data. Disease progression without DMTs was taken from an epidemiological cohort in France (EDMUS cohort, LYON). Progression under DMTs was estimated from the Stockholm MS registry. Results are presented as cost per quality-adjusted life-years (QALYs), from the societal perspective, in EUR2007, discounted at 3%. </jats:p><jats:p> Results </jats:p><jats:p> Mean Expanded Disability Status Scale (EDSS) was 4.4 and mean total annual costs per patient were EUR44,400, of which 47% were productivity losses and 11% informal care. Public payers cover an estimated 48% of costs. Mean utility was 0.52, and the loss compared with the normal population was estimated at 0.28. Costs and utility ranged from EUR16,000 and 0.79 at EDSS 1 to EUR76,000 and 0.11 at EDSS 8–9. </jats:p><jats:p> Over 20 years, costs were estimated at EUR429,000 and QALYs at 8.96 for patients without DMTs and at EUR433,207 and 9.24 QALYs if all patients were starting treated with DMTs at EDSS 1–3. </jats:p><jats:p> Conclusion </jats:p><jats:p> Although the data for this analysis come from different sources, the results indicate that the cost increase with DMTs is moderate. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509102771", "published_date": "2009-04-21T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 289903, "given_name": "G", "family_name": "Kobelt", "ORCID": null, "country": null }, { "author_id": 302284, "given_name": "B", "family_name": "Texier-Richard", "ORCID": null, "country": null }, { "author_id": 292974, "given_name": "P", "family_name": "Lindgren", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.980260Z", "noun_phrases": [ "The long-term cost", "multiple sclerosis", "France", "potential changes", "disease-modifying interventions" ], "doi": "10.1177/1352458509102771", "access": "restricted", "takeaways": " Data on resource consumption, productivity losses, QoL (utility), and fatigue were collected from 1355 patients registered with a patient association . Disease progression without DMTs was taken from an epidemiological cohort in France (EDMUS cohort, LYON) Progression under DMT was estimated from the Stockholm MS registry . Over 20 years, costs were estimated at EUR429,000 and QALYs at 8.96 for patients without the treatment .", "categories": [] }, { "article_id": 439286, "title": "The search for responsive clinical endpoints in primary progressive multiple sclerosis", "summary": "<jats:p> Objective </jats:p><jats:p> To determine whether in primary progressive multiple sclerosis (PPMS) combining scores of Expanded Disability Status Scale (EDSS) with data from Timed 25-Foot Walk (T25FW) and 9-Hole Peg Test (9HPT) would produce a clinical endpoint that has a higher event rate than EDSS alone. </jats:p><jats:p> Methods </jats:p><jats:p> In a group of 161 PPMS patients, EDSS, T25FW, and 9HPT were performed at three time points over 2 years. We calculated how many patients showed clinically meaningful deterioration (or improvement) on individual and combined scales. We defined improvements on one scale with deterioration on the other as “opposing changes.” We investigated the possible effect of baseline disability on the definition of our endpoint by dividing the population into two subsets of patients determined by baseline EDSS level. </jats:p><jats:p> Results </jats:p><jats:p> On individual scales, event rates were highest on T25FW: 34% and 46% 1 year and 2 years after baseline. On a combination of two scales, at 1 year the event rate was highest on T25FW/9HPT (46%; with a high rate of opposing changes) and at 2 years on T25FW/EDSS (57%; with a lower rate of opposing changes). In both subsets, event rates were highest on T25FW and (at 2 years) on the combination of T25FW/EDSS. </jats:p><jats:p> Conclusions </jats:p><jats:p> T25FW has the highest event rate as a single scale, independent of baseline disability level. A term of 2 years turned out to be more meaningful to observe than 1 year. “Worsening on either T25FW or EDSS” is the most appropriate composite endpoint in this patient group. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509102626", "published_date": "2009-04-21T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 272070, "given_name": "LVAE", "family_name": "Bosma", "ORCID": null, "country": null }, { "author_id": 241448, "given_name": "JJ", "family_name": "Kragt", "ORCID": null, "country": null }, { "author_id": 269366, "given_name": "L", "family_name": "Brieva", "ORCID": null, "country": null }, { "author_id": 271992, "given_name": "Z", "family_name": "Khaleeli", "ORCID": null, "country": null }, { "author_id": 246272, "given_name": "X", "family_name": "Montalban", "ORCID": null, "country": null }, { "author_id": 241203, "given_name": "CH", "family_name": "Polman", "ORCID": null, "country": null }, { "author_id": 251315, "given_name": "AJ", "family_name": "Thompson", "ORCID": null, "country": null }, { "author_id": 255585, "given_name": "M", "family_name": "Tintoré", "ORCID": null, "country": null }, { "author_id": 250179, "given_name": "BMJ", "family_name": "Uitdehaag", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.978936Z", "noun_phrases": [ "The search", "responsive clinical endpoints", "primary progressive multiple sclerosis" ], "doi": "10.1177/1352458509102626", "access": "restricted", "takeaways": " In a group of 161 PPMS patients, EDSS, T25FW, and 9HPT were performed at three time points over 2 years . We calculated how many patients showed clinically meaningful deterioration (or improvement) on individual and combined scales . We defined improvements on one scale with deterioration on the other as “opposing changes”", "categories": [] }, { "article_id": 439285, "title": "Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity", "summary": "<jats:p> Background </jats:p><jats:p> Detrusor overactivity is often observed in patients with multiple sclerosis (MS), and neurotoxins are emerging as second-line therapies albeit with different degrees of success per patient basis. </jats:p><jats:p> Objective </jats:p><jats:p> To investigate lower urinary tract (LUT) functional status and bladder innervation (calcitonin gene related peptide [CGRP] and substance P [SP] positive nerve fibers) in patients with MS. </jats:p><jats:p> Method </jats:p><jats:p> Eighteen MS patients with LUT symptoms underwent urodynamic investigations, and six non-MS patients undergoing cystoscopy due to microscopic hematuria served as controls. Cold cut bladder biopsies were taken from the bladder trigone region. Neurotransmitter expression was determined by individual immunohistochemical staining. </jats:p><jats:p> Results </jats:p><jats:p> Two distinct groups could be distinguished: group 1 with pronounced neurogenic detrusor overactivity and mild outflow obstruction; group 2 with some degree of neurogenic detrusor overactivity, detrusor hypocontractility during voiding, and high degree of an outflow obstruction. The presence of SP and CGRP immunoreactive + fiber density was observed in greater numbers in group 1. </jats:p><jats:p> Conclusion </jats:p><jats:p> Density of CGRP and SP positive nerve fibers within the urinary bladder of patients with MS may be suggestive of functional status of the lower urinary tract, namely denser innervation is observed in patients with mild outflow obstruction and strong detrusor overactivity. This observation could be useful when planning second-line treatment (neurotoxins) in these patients. Patients with denser innervation probably will respond better to such a therapy. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509106210", "published_date": "2009-06-19T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 308624, "given_name": "P", "family_name": "Radziszewski", "ORCID": null, "country": null }, { "author_id": 308625, "given_name": "R", "family_name": "Crayton", "ORCID": null, "country": null }, { "author_id": 308626, "given_name": "J", "family_name": "Zaborski", "ORCID": null, "country": null }, { "author_id": 308627, "given_name": "A", "family_name": "Członkowska", "ORCID": null, "country": null }, { "author_id": 308628, "given_name": "A", "family_name": "Borkowski", "ORCID": null, "country": null }, { "author_id": 308629, "given_name": "A", "family_name": "Bossowska", "ORCID": null, "country": null }, { "author_id": 308630, "given_name": "M", "family_name": "Majewski", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.977685Z", "noun_phrases": [ "Multiple sclerosis", "significant changes", "urinary bladder innervation", "which", "the lower urinary tract functional status-sensory nerve fibers role", "detrusor overactivity" ], "doi": "10.1177/1352458509106210", "access": "restricted", "takeaways": " Detrusor overactivity is often observed in patients with multiple sclerosis . Neurotransmitter expression was determined by individual immunohistochemical staining . Density of CGRP and SP positive nerve fibers within the urinary bladder of patients with MS may be suggestive of functional status of the lower urinary tract . Patients with denser innervation probably will respond better to such a therapy .", "categories": [] }, { "article_id": 439284, "title": "Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study", "summary": "<jats:p> Background </jats:p><jats:p> Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing–remitting (RR) MS is unclear. </jats:p><jats:p> Objectives </jats:p><jats:p> To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. </jats:p><jats:p> Methods </jats:p><jats:p> Patients aged 18–50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ≤4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. </jats:p><jats:p> Results </jats:p><jats:p> A total of 550 patients were enrolled, 327 of whom underwent MRI assessments. Cognitive impairment (impaired performance in ≥3 cognitive tests) was present in approximately 20% of all patients and in the subgroup who underwent MRI. T2 hyperintense and T1 hypointense lesion volumes were significantly higher in patients with cognitive impairment (defined as impaired performance on at least three tests of the Rao’s battery) than those without. EDSS score was also significantly higher in cognitively impaired than in cognitively preserved patients. Disease duration, depression, and years in formal education did not differ significantly between cognitively impaired and cognitively preserved patients. T2 lesion volume, performance intelligence quotient, and age were significant predictors of cognitive impairment in this population. Weak correlations were found between performance on individual cognitive tests and specific MRI measures, with T1 and T2 lesion volumes correlating with performance on most cognitive tests. </jats:p><jats:p> Conclusions </jats:p><jats:p> Cognitive impairment occurs in approximately one-fifth of mildly disabled patients with MS and is associated with specific MRI disease measures. Assessment of cognitive function at diagnosis could facilitate the identification of patients who may benefit from therapeutic intervention with disease-modifying therapies to prevent further lesion development. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458509105544", "published_date": "2009-06-19T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 241595, "given_name": "F", "family_name": "Patti", "ORCID": null, "country": null }, { "author_id": 241601, "given_name": "MP", "family_name": "Amato", "ORCID": null, "country": null }, { "author_id": 241600, "given_name": "M", "family_name": "Trojano", "ORCID": null, "country": null }, { "author_id": 266842, "given_name": "S", "family_name": "Bastianello", "ORCID": null, "country": null }, { "author_id": 275417, "given_name": "MR", "family_name": "Tola", "ORCID": null, "country": null }, { "author_id": 241588, "given_name": "B", "family_name": "Goretti", "ORCID": null, "country": null }, { "author_id": 309917, "given_name": "L", "family_name": "Caniatti", "ORCID": null, "country": null }, { "author_id": 309918, "given_name": "E", "family_name": "Di Monte", "ORCID": null, "country": null }, { "author_id": 309919, "given_name": "P", "family_name": "Ferrazza", "ORCID": null, "country": null }, { "author_id": 255478, "given_name": "V", "family_name": "Brescia Morra", "ORCID": null, "country": null }, { "author_id": 309920, "given_name": "S", "family_name": "Lo Fermo", "ORCID": null, "country": null }, { "author_id": 309921, "given_name": "O", "family_name": "Picconi", "ORCID": null, "country": null }, { "author_id": 303939, "given_name": "G", "family_name": "Luccichenti", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:09.976102Z", "noun_phrases": [ "Cognitive impairment", "its relation", "disease measures", "mildly disabled patients", "multiple sclerosis", "baseline results", "the Cognitive Impairment", "Multiple Sclerosis" ], "doi": "10.1177/1352458509105544", "access": "restricted", "takeaways": " Cognitive impairment occurs in approximately one-fifth of mildly disabled patients with MS and is associated with specific MRI disease measures . T2 lesion volume, performance intelligence quotient, and age were significant predictors of cognitive impairment in this population .", "categories": [] } ] }